Expert Recommendations for the Diagnosis and Treatment of Axial Spondyloarthritis

1.00 CME
$0 FEE
Expert Recommendations for the Diagnosis  and Treatment of Axial Spondyloarthritis


Provider Statement

Provided by Purdue University College of Pharmacy

Support Statement

This activity is supported by educational grants from AbbVie Inc. and Novartis Pharmaceuticals Corporation.

Activity Description

In this interactive multimedia presentation, gain expert insights on current guidelines and best practice for your patients with axial spondyloarthritis.

Target Audience

This educational activity is intended for rheumatologists, primary care physicians, and other clinicians managing patients with axSpA. 

Learning Objectives

Upon successful completion of this educational activity, participants should be better able to:

  • Describe the evaluation of patients who may have axSpA including clinical presentation, laboratory studies, and appropriate imaging studies to improve early diagnosis
  • Review the ASAS classification criteria for axSpA
  • Discuss extra-articular manifestations and QoL concerns seen in patients with axSpA
  • Apply the guideline recommendations for the management of axSpA
  • Describe agents in late-stage development for axSpA


Program Director

Atul Deodhar, MD
Professor of Medicine
Medical Director, Rheumatology Clinics
Division of Arthritis and Rheumatic Diseases
Oregon Health & Science University
Portland, Oregon


M. Susan Burke, MD, FACP
Clinical Associate Professor of Medicine
Department of Internal Medicine
Sidney Kimmel Medical College at Thomas Jefferson University
Philadelphia, Pennsylvania
Senior Advisor
Lankenau Medical Associates
Lankenau Medical Center
Wynnewood, Pennsylvania

Marina N. Magrey, MD
Associate Professor of Medicine
Division of Rheumatology
Department of Medicine
Case Western Reserve University School of Medicine
Director, Rheumatology Fellowship
MetroHealth Medical Center
Cleveland, Ohio 


Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Purdue University College of Pharmacy and Clinical Care Options, LLC. Purdue University is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Purdue University designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

How to Participate in This Activity and Obtain CME Credit

Participation in this self-study activity should be completed in approximately 1.0 hour. To successfully complete this activity and receive credit, participants must:
1. Read the target audience, learning objectives, and faculty disclosures.
2. Study the educational activity online or printed out.
3. Submit answers to the posttest questions and evaluation questions online 

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate.


All faculty, staff and reviewers involved in the planning, review or presentation of continuing education activities provided by Purdue University College of Pharmacy are required to disclose to the audience any relevant commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. All additional planning committee members, staff and reviewers of Clinical Care Options, LLC and Purdue University College of Pharmacy have no relationships to disclose. 

Faculty report the following relationship(s)

Atul Deodhar, MD, has disclosed that he has received consulting fees from and has served on advisory boards for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Galapagos, GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer, and UCB and has received funds for research support from AbbVie, GlaxoSmithKline, Lilly, Novartis, Pfizer, and UCB. 

M. Susan Burke, MD, FACP, has no relevant conflicts of interest to report. 

Marina N. Magrey, MD, has disclosed that she has received consulting fees from and has served on advisory boards for Janssen, Lilly, Novartis, Pfizer, and UCB and has received funds for research support from AbbVie and UCB.

CCO Staff report the following relationship(s)

Zachary Schwartz, MSc, Kiran D. Mir-Hudgeons, PhD, Pranali Pathare, PhD, and Anne Roc, PhD have no relevant conflicts of interest to report. 

Unlabeled and Investigational Usage

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.

Purdue University requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications.